Skip to content
Stock screener

LLY ELI LILLY & Co stock chart & analysis

Conviction 28HealthcareScan · Fri, Nov 6, 2026

ELI LILLY & Co (LLY) closed at $1,354.00 (-0.79%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 61, RS Rating 93, -6.8% from its 52-week high, +26.1% year to date. Sector: Healthcare · Pharmaceutical Preparations.

LLY$1,354.00-0.79%
ResistanceSupportVol 14Insider sellCongress buyCongress sell
Loading chart…
ELI LILLY & CoPharmaceutical Preparationswww.lilly.com ↗
Price1,354.00
Change-0.79%
Gap-2.04%
Rel volume1.53×
Avg volume2.96M
Avg $ vol3.92B
SMA 201,302.00
SMA 501,214.27
SMA 2001,099.64
Price vs 50+11.59%
Price vs 200+23.22%
MA stackbullish
50/200 cross—
Supertrendup · 1,283.83
RSI (14)61
MACD hist5.15
MACD cross—
Stoch %K / %D50 / 65
ADX (14)39
+DI / −DI31 / 19
RSI divergence—
MACD divergence—
ATR %3.48%
ADR %3.10%
52w high1,453.00
52w low850.51
From 52w high-6.75%
Above 52w low+59.31%
New 52w highNo
SqueezeOff
Bollinger width23.30%
%B0.67
Donchian pos66.72%
Donchian high1,453.00
Donchian low1,158.41
AVWAP (52w high)1,376.15
vs AVWAP high-1.54%
AVWAP (52w low)1,157.77
vs AVWAP low+17.03%
OBV trendUp
Chaikin MF (20)-0.17
Today vs 20d1.53×
Avg vol (14d)3.2M
Avg vol (20d)2.96M
Avg $ vol (20d)3.92B
Market cap1.27T
RS Rating93 / 99
RS 3m (vs SPY)+14.85%
RS 6m (vs SPY)+43.16%
RS line new highNo
Trend template8/8
Technical rank91.3
1 week-4.41%
1 month+15.85%
3 months+9.99%
6 months+42.86%
1 year+46.35%
YTD+26.08%
P/E61.76
P/B31.65
P/S19.56
P/FCF—
EPS22.95
Div yield0.42%
ROE51.25%
ROA13.94%
Debt/Eq1.23
Current1.39
EV/EBITDA—
Gross margin83.04%
Net margin31.67%
Rev growth44.70%
EPS growth94.90%
Price target1,511.30
Target upside11.54%
Analyst ratingBuy
Institutional107.41%
Ent. value1.32T
Revenue24.4B
Net income6.45B
Gross profit20.46B
Free cash flow—
IndustryPharmaceutical Preparations
ExchangeNYSE
Shares out941.74M
Employees50K
ListedThu, Jul 9, 1970
Free float851.28M
Float %90.1%
Short interest—
Days to cover—
Short volume24.7%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est$7.48 vs $5.38
Last surprise+39.0% beat
Setup gradeD
Conviction28 / 100
Pattern quality—
Tech rank91.3 / 100
Group rank23 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance1,385.45
Support1,134.09
Days since event—
Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

LLY technical analysis

Trend

LLY is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 11.6% above the 50-day ($1,214.27) and 23.2% above the 200-day ($1,099.64). ADX(14) at 39 points to a strong, established trend. It meets 8 of 8 trend-template criteria.

Momentum

RSI(14) is 61, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 93 puts its weighted 12-month performance ahead of about 93% of the US market.

Volume and volatility

Volume on the latest session ran 1.5× its 20-day average. It trades about $3.9B a day on average. ATR(14) is $47.15, 3.5% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.17) shows distribution.

Key levels

The chart pattern's support is $1,134.09 and its resistance $1,385.45. The 52-week range is $850.51 to $1,453.00; price is 6.8% below the high and 59.3% above the low. The VWAP anchored at the 52-week high is $1,376.15, above price.

Performance

LLY returned -4.4% (1 week), +15.8% (1 month), +10.0% (3 months), +42.9% (6 months), +46.4% (1 year), +26.1% (year to date).

About ELI LILLY & Co

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Pharmaceutical Preparations · Listed 1970 · 50,000 employees

Signal lifecycle

How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.

  1. Setting up
    Oct 14
    1 scan
  2. Breaking out now
    Oct 15
    1 scan
  3. Setting up
    Oct 28
    1 scan

Congress activity

Disclosed STOCK Act trades in LLY · 10 recent

All disclosures →
MemberSideAmount
John Boozman
John Boozman
senate · R · AR · traded 2025-11-21
Sell$1K–$15K
Michael Rulli
Michael Rulli
house · R · OH · traded 2025-12-02
Sell$1K–$15K
Michael Rulli
Michael Rulli
house · R · OH · traded 2026-07-01
Sell$1K–$15K
Michael Rulli
Michael Rulli
house · R · OH · traded 2026-01-02
Buy$1K–$15K
Thomas H Tuberville
Thomas H Tuberville
senate · traded 2025-04-15
Sell$15K–$50K
Alan Armstrong
Alan Armstrong
senate · R · OK · traded 2026-03-27
Sell$1K–$15K
Dan Newhouse
Dan Newhouse
house · R · WA · traded 2026-07-10
Sell$1K–$15K
Gilbert Cisneros
Gilbert Cisneros
house · D · CA · traded 2026-06-10
Buy$50K–$100K
Gilbert Cisneros
Gilbert Cisneros
house · CA · traded 2026-04-14
Buy$1K–$15K
Byron Donalds
Byron Donalds
house · FL · traded 2026-04-02
Buy$1K–$15K

Insider activity

SEC Form 4 transactions in LLY · open-market 1 sell

InsiderSideShares
Ricks David A
President, Chair, and CEO · Common Stock · 2026-11-03
Gift23.54K
Skovronsky Daniel
EVP, CS&PO & Pres. LRL · Common Stock · 2026-11-02
Gift119
Hakim Anat
EVP, GC & Secretary · Common Stock · 2026-11-02
Sell5K
Brown Adrienne S
EVP, President LLY Imm · Restricted Stock Unit · 2026-11-01
Exercise2.53K
Custer Kenneth L.
EVP & President, Card Met Hlth · Common Stock · 2026-11-01
Exercise3.22K
Custer Kenneth L.
EVP & President, Card Met Hlth · Common Stock · 2026-11-01
Tax1.43K
Custer Kenneth L.
EVP & President, Card Met Hlth · Restricted Stock Unit · 2026-11-01
Exercise3.22K
Dozier Eric
EVP, Chief People Officer · Common Stock · 2026-11-01
Exercise2.3K
Dozier Eric
EVP, Chief People Officer · Common Stock · 2026-11-01
Tax1.02K
Dozier Eric
EVP, Chief People Officer · Restricted Stock Unit · 2026-11-01
Exercise2.3K

SEC filings

EDGAR filings in LLY · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.